BioAffinity Technologies

BioAffinity Technologies bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and targeted cancer treatment.

The Company’s first product, CyPath® Lung, is a noninvasive test for people at high risk for lung cancer.

01/30/2026

In a recent presentation, Dr. Michael Nicholson explains how he uses CyPath® Lung in his pulmonology practice. The noninvasive diagnostic test for lung cancer is an effective tool for:
• Managing indeterminate lung nodules
• Risk stratifying patients at high risk for lung cancer
• Reducing uncertainty and patient anxiety with noninvasive testing

Earlier answers for better-informed decision-making.

Watch w/ free subscription at https://bit.ly/4qk8txm

Thank you to for supporting physician education and dialogue on advances in lung health.

01/30/2026

When early detection matters, clarity matters, CyPath® Lung gives physicians answers within 72 hours of a viable sample being returned to our lab. Physicians are talking … be a part of the conversation.

Lung cancer experts stress the importance of lung cancer screening and value of expanding screening criteria to include ...
01/27/2026

Lung cancer experts stress the importance of lung cancer screening and value of expanding screening criteria to include more at-risk individuals. See the article in Oncology Live at https://bit.ly/4k5NBbA
See how CyPath® Lung can help at www.cypathlung.com

Dr. Martin Luther King Jr. reminded us that injustice in healthcare is among "the most shocking and inhuman" forms of in...
01/19/2026

Dr. Martin Luther King Jr. reminded us that injustice in healthcare is among "the most shocking and inhuman" forms of inequality. Expanding access to noninvasive diagnostic tools is one way we can improve access and reduce barriers for all patients at risk for lung cancer. We honor Dr. King's legacy today and every day.

Good news: Lung cancer cases in Texas are declining.Hard truth: We’re still not catching it early enough, especially in ...
01/15/2026

Good news: Lung cancer cases in Texas are declining.

Hard truth: We’re still not catching it early enough, especially in Black and Latino communities.

Only 12% of high-risk Texans receive recommended lung cancer screening — ranking Texas 46th nationally. Early detection and access matter.

📊 American Lung Association, 2025 State of Lung Cancer
Read the report at https://bit.ly/4qVmRwy

01/14/2026

Physicians are talking…
See what Dr. Greg White, Christus Trinity Clinic, has to say about the benefits of adding CyPath® Lung to his practice.

We’re excited to welcome Amy Garcia as a new Patient Coach on the CyPath® Lung team! Amy brings incredible energy, compa...
01/08/2026

We’re excited to welcome Amy Garcia as a new Patient Coach on the CyPath® Lung team! Amy brings incredible energy, compassion, and dedication to guiding patients through their testing journey, ensuring they feel informed, supported, and confident every step of the way. We’re thrilled to have her on board!

Precision Pathology Laboratory Services has successfully maintained the gold standard for laboratory quality and patien...
01/07/2026

Precision Pathology Laboratory Services has successfully maintained the gold standard for laboratory quality and patient safety with its CAP accreditation. This reinforces the high standards behind our noninvasive CyPath® Lung test, which can detect lung cancer as early as Stage 1A and improve patient outcomes.
Read the press release🔗https://bit.ly/4q5k9Va

As the year comes to a close, we’re inspired by what’s possible when innovation meets compassion. At CyPath® Lung, we re...
12/31/2025

As the year comes to a close, we’re inspired by what’s possible when innovation meets compassion. At CyPath® Lung, we remain committed to advancing noninvasive testing and supporting better outcomes in the year ahead.
Happy Holidays and best wishes for a healthy New Year!

When Barry Manilow publicly shared his lung cancer diagnosis, his story underscored a powerful truth: early detection sa...
12/22/2025

When Barry Manilow publicly shared his lung cancer diagnosis, his story underscored a powerful truth: early detection saves lives.
Too often, lung cancer is found late. At bioAffinity Technologies, we’re working to change that with CyPath® Lung, our noninvasive, sputum-based test designed to help identify cancer as early as Stage 1A.
We wish Mr. Manilow the best for a full and speedy recovery.

Proud to announce our Chief Medical Officer, Gordon Downie, MD, PhD, will present recent case studies at the American Ca...
12/03/2025

Proud to announce our Chief Medical Officer, Gordon Downie, MD, PhD, will present recent case studies at the American Cancer Society National Lung Cancer Roundtable on Monday, December 8, 2025, from 2:35-3:15 p.m. ET.
His poster highlights three challenging patient cases in which CyPath® Lung helped identify Stage 1A lung cancer despite conflicting or inconclusive diagnostic data.

Read the full press release and view the poster here➡ https://bit.ly/3MdSP8i

11/26/2025

Would CyPath® Lung be right for your patient?

Address

3300 Nacogdoches Road Ste 216
San Antonio, TX
78217

Telephone

+12106985334

Website

Alerts

Be the first to know and let us send you an email when BioAffinity Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram